Household Product Labeling Act of 2009

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th H.R. 2751, FDA Food Safety Modernization Act (Senate version S. 510) The Breast Cancer Fund supported efforts to pass this legislation because of a possible amendment to ban bisphenol-A, a chemical linked to increased rates of cancer, as well as other significant health problems, from certain food contact materials. The Breast Cancer Fund met with staff from various offices to encourage support for this language and eventual passage of the bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Client expense: Not reported · Firm income: $40,000

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE

H.R. 3057 and S. 1697 product ingredient communication and product safety issues

Client expense: $111,000 · Firm income: Not reported

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE

Implementation of Consumer Product Safety Improvement Act (CPSIA) of 2008 S.1697 Household Product Labeling Act of 2009 HR.3057 Household Product labeling Act of 2009 Enhancements to the Consumer Product Safety Improvement Act

Client expense: $1,030,211 · Firm income: Not reported

Government targets: Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 111th House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209) The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced) The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Client expense: Not reported · Firm income: $40,000

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE

H.R. 2350/1174; Preserving Patient Access to Primary Care Act of 2009 H.R. 2730; Student to School Nurse Ratio Improvement Act of 2009 S. 1303; Women's Medical Home Demonstration Act All provisions related to Certified Nurses Day Resolution (H. Res. 1158) H.R. 5270; Improving access to workers compensation for Injured Federal Workers Act H.R. 5040; Health Information Technology Extension for Behavioral health Services Act of 2010 H.R. 1191: Safe Drug Disposal S. 27/H.R. 2043: Nurse Education, Expansion and Development Act of 2009 (NEED Act) Provisions related to a resolution regardining Safe Patient Handling and Movement Initiative (H. Res. 510). S. 1267; Evidence-Based Home Visitation Act of 2009 H.R. 1946; Health Workforce Investment Act of 2009 H.R. 2371; Nurse Training and Retention Act of 2009 S. 1796; America's Healthy Future Act S. 1697; Affordable Health Choices Act H.R. 3191; Positive Aging Act of 2009 H.R. 1460/S. 1022; The Nurses Higher Education and Loan Repayment Act of 2002 H.R. 2535; Blueprint for Health Act of 2009 The Health Equity and Accountability Act of 2009 H.R. 2381/S. 1788; The Nurse and Health Care Worker Protection Act of 2009 S. 1679; Affordable Health Choices Act - Resonable Break Time for Nursing Mothers U.S. Food and Drug Administration, related to re-evaluation of BPA H.R. 4993/S. 2814; Home Health Care Planning Improvement Act of 2009 S.A. 2928; "To include Direct Care Workers as a priority for the National Health Care Workforce Commission" H.R. 4601; National Nurse Act of 2010, provisions related to creation of the Office of the National Nurse Women's Health Admendment (Sec. 271(a)(4)) of Public Service Act H.R. 5742; Medical Checklist Act of 2010

Client expense: $401,501 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE

H.R. 3057 and S. 1697, product ingredient communication and product safety issues

Client expense: $140,000 · Firm income: Not reported

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund has met with staff from various House and Senate offices about future legislation to reform the Estrogenic Substances Screening Program at EPA with the goal of identifying and removing estrogenic compounds in our nations drinking supply that currently increase the risk of breast cancer incidence. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process. S.3209, the Safe Chemicals Act of 2010 (House bill not yet introduced). The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.

Client expense: Not reported · Firm income: $40,000

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

Implementation of Consumer Product Safety Improvement Act (CPSIA) of 2008 S.1697 Household Product Labeling Act of 2009 HR.3057 Household Product labeling Act of 2009 Enhancements to the Consumer Product Safety Improvement Act

Client expense: $1,079,067 · Firm income: Not reported

Government targets: Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)

H.R. 3057 & S. 1697 product ingredient communication and product safety issues

Client expense: $190,000 · Firm income: Not reported

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE

H.R. 2350/1174; Preserving Patient Access to Primary Care Act of 2009 H.R. 2730; Student to School Nurse Ratio Improvement Act of 2009 S. 1303; Women's Medical Home Demonstration Act All provisions related to the National Nurse Week Resolution (H. Res 1261) All provisions related to Certified Nurses Day Resolution (H. Res. 1158) H.R. 5270; "Improving access to workers compensation for Injured Federal Workers Act H.R. 5040; Health Information Technology Extension for Behavioral Health Services Act of 2010 H.R. 1191; Safe Drug Disposal S. 27H.R. 2043; Nurse Education, Expansion, and Development Act of 2009 (NEED Act) Provisions related to a resolution regarding Safe Patient Handling and Movement initiative (H. Res. 510). S. 1267; Evidence-Based Home Visitation Act of 2009 H.R. 1946; Health Workforce Investment Act of 2009 H.R. 2371; Nurse Training and Retention Act of 2009 S. 1796; America's Healthy Future Act S. 1697; Affordable Health Choices Act H.R. 3191; Positive Aging Act of 2009 H.R. 1460/S.1022; The Nurses Higher Education and Loan Repayment Act of 2002 H.R. 2535; Blueprint for Health Act of 2009 The Health Equity and Accountability Act of 2009 H.R. 3962; Affordale Health Care for America Act H.R. 2381/S. 1788; The Nurse and Health Care Worker Protection Act of 2009 S. 1679; Affordable Health Choices Act - Resonable Break Time for Nursing Mothers U.S. Food and Drug Administration, related to re-evaluation of BPA H.R. 4993/S. 2814; Home Health Care Planning Improvement Act of 2009 SA. 2928; "To include Direct Care Workers as a priority for the National Health Care Workforce Commission" H.R. 4872; Health Care and Education Affordability Reconciliation Act H.R. 4601; National Nurse Act of 2010, provisions related to creation of the Office of the National Nurse

Client expense: $468,758 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation in the 111th H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697) The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828) The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund has met with staff from various House and Senate offices about future legislation to reform the Estrogenic Substances Screening Program at EPA with the goal of identifying and removing estrogenic compounds in our nations drinking supply that currently increase the risk of breast cancer incidence. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. P.L. 110-314 The Consumer Product Safety Commission Improvement Act This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation. P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Client expense: Not reported · Firm income: $40,000

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

Implementation of Consumer Product Safety Improvement Act (CPSIA) of 2008 S.1697 Household Product Labeling Act of 2009 HR.3057 Household Product labeling Act of 2009 Enhancements to the Consumer Product Safety Improvement Act

Client expense: $1,046,127 · Firm income: Not reported

Government targets: Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)

H.R. 3200: America's Affordable Health Choices Act of 2009, and other health care reform proposals under consideration S. 1697:Community Living Assistance Services and Supports Act (CLASS Act) H.R. 3590: Patient Protection and Affordable Care Act. H.R. 4097: Healthcare and Education Affordability Reconciliation Act

Client expense: $305,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Labor, Dept of (DOL), SENATE, White House Office

H.R. 2868, Chemical Facilty Anti-Terrorism ACt of 2009 H.R. 3057, S. 1697, Ingredient Disclosure legislation Proposed legislation on reform of the Toxic Substances Control Act and on endocrine disruption

Client expense: $290,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

H.R. 3057 & S. 1697 product ingredient communication and product safety issues

Client expense: $100,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE

Legislation to reform private health insurance. Legislation and policies affecting Medicare, Medicaid and healthcare generally, Health I.T. - HR 6357, Healthcare reform, HR 3200 and S. 1697. Oversight of health insurance market generally.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation to reform private health insurance. Legislation and policies affecting Medicare, Medicaid and healthcare generally, Health I.T. - HR 6357, Healthcare reform, HR 3200 and S. 1697. Oversight of health insurance market generally.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Implementation of Consumer Product Safety Improvement Act (CPSIA) of 2008 S.1697 Household Product Labeling Act of 2009 HR.3057 Household Product labeling Act of 2009

Client expense: $824,821 · Firm income: Not reported

Government targets: Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)

H.R. 3200: America's Affordable Health Choices Act of 2009, and various health care reform proposals currently under consideration in Congressional committees. S. 1697:Community Living Assistance Services and Supports Act (CLASS Act) H.R. 3590: Patient Protection and Affordable Care Act.

Client expense: $350,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Labor, Dept of (DOL), SENATE, White House Office

H.R. 3200: America's Affordable Health Choices Act of 2009, and various health care reform proposals currently under consideration in Congressional committees. S. 1697:Community Living Assistance Services and Supports Act (CLASS Act) H.R. 3590: Patient Protection and Affordable Care Act.

Client expense: $350,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Labor, Dept of (DOL), SENATE, White House Office

S. 1697 Affordable Health Choices Act S. 1796 America's Health Choices Act H.R. 3200 America's Affordable Health Choices Act Regulatory provisions related to Medicare Part D. Provisions included in health reform proposals that would impact Part D, such as formulary requirements, anti-kickback statutes for generic drug copay waivers, Medicaid rebate changes, direct negotiation.

Client expense: $18,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

S. 1697 Affordable Health Choices Act S. 1796 America's Health Choices Act H.R. 3200 America's Affordable Health Choices Act H.R. 1427/S. 726 promoting Innovation and Access to Life Saving Medications Act H.R. 1549 Pathway for Biosimilars Act Provisions related to settlement payments between manufacturers to delay introduction of generic pharmaceutical products Benefit design and coverage of pharmaceutical benefits in health and PBM disclosure in health reform proposals Health Care Reform, Follow-on Biologics, Pharmaceutical Benefits, Comparative Effectiveness Research, Public Plan Option, Pharmaceutical Pricing, Generic Pharmaceuticals, Health IT, Medicare Part D, Medicaid, Pharmacy Networks and Contracting

Client expense: $18,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

S. 1697 Affordable Health Choices Act S. 1796 America's Health Choices Act H.R. 1204 Community Pharmacy Fairness Act H.R. 3200 America's Affordable Health Choices Act H.R. 1427/S. 726 promoting Innovation and Access to Life Saving Medications Act H.R. 1549 Pathway for Biosimilars Act Health Care Reform, Follow-on Biologics, Pharmaceutical Benefits, Comparative Effectiveness Research, Public Plan Option, Pharmaceutical Pricing, Generic Pharmaceuticals, Health IT, Medicare Part D, Medicaid, Pharmacy Networks and Contracting

Client expense: $18,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

S. 1697 Affordable Health Choices Act S. 1796 America's Health Choices Act H.R. 1204 Community Pharmacy Fairness Act H.R. 3200 America's Affordable Health Choices Act H.R. 1427/S. 726 promoting Innovation and Access to Life Saving Medications Act H.R. 1549 Pathway for Biosimilars Act Health Care Reform, Follow-on Biologics, Pharmaceutical Benefits, Comparative Effectiveness Research, Public Plan Option, Pharmaceutical Pricing, Generic Pharmaceuticals, Health IT, Medicare Part D, Medicaid, Pharmacy Networks and Contracting

Client expense: $18,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Chemicals Management, including potential reform of the Toxic Substances Control Act. No specific legislation introduced as of yet. Bills introduced on ingredient disclosure, S. 1697 and H.R. 3057

Client expense: $330,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Proposed rule for CY2010 Physician Fee Schedule, S. 2029 Physician Payments Sunshine Act, Affordable Health Care for America Act (final House bill HR 3962), Affordable Health Choices Act (S. 1697), Patient Protection and Affordable Care Act (HR 3590)

Client expense: $130,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, U.S. Customs & Border Protection

Comparative Effectiveness Research Act (S. 3408), Affordable Health Care for America Act (final House bill HR 3962), Affordable Health Choices Act (S. 1697), Patient Protection and Affordable Care Act (HR 3590)

Client expense: $130,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, U.S. Customs & Border Protection

H.R. 3057 & S. 1697 product ingredient and consumer product safety issues

Client expense: $70,000 · Firm income: Not reported

Government targets: Consumer Product Safety Commission (CPSC), Council on Environmental Quality (CEQ), Environmental Protection Agency (EPA), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, White House Office

H.R. 3057 & S. 1697 product ingredient communication and consumer product safety issues

Client expense: $100,000 · Firm income: Not reported

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE, White House Office

H.R. 3057 & S. 1697, product ingredient communication and consumer product safety issues

Client expense: $100,000 · Firm income: Not reported

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE, White House Office

S. 1697 Affordable Health Choices Act S. 1796 America's Healthy Choices Act H.R. 1204 Community Pharmacy Fairness Act H.R. 3200 America's Affordable Health Choices Act H.R. 1427/S. 726 Promoting Innovation and Access to Life Saving Medications Act H.R. 1549 Pathway for Biosimilars Act Health Care Reform, Follow-on Biologics, Pharmacy Benefits, Comparative Effectiveness Research, Public Plan Option, Pharmaceutical Pricing, Generic Pharmaceuticals, Healht IT, Medicare Part D, Medicaid, Pharmacy Networks and Contracting

Client expense: $52,597 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

S. 1697 Affordable Health Choices Act S. 1796 America's Healthy Choices Act H.R. 1204 Community Pharmacy Fairness Act H.R. 3200 America's Affordable Health Choices Act H.R. 1427/S. 726 Promoting Innovation and Access to Life Saving Medications Act H.R. 1549 Pathway for Biosimilars Act Health Care Reform, Follow-on Biologics, Pharmacy Benefits, Comparative Effectiveness Research, Public Plan Option, Pharmaceutical Pricing, Generic Pharmaceuticals, Healht IT, Medicare Part D, Medicaid, Pharmacy Networks and Contracting

Client expense: $52,597 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

S. 1697 Affordable Health Choices Act S. 1796 America's Healthy Choices Act H.R. 1204 Community Pharmacy Fairness Act H.R. 3200 America's Affordable Health Choices Act H.R. 1427/S. 726 Promoting Innovation and Access to Life Saving Medications Act H.R. 1549 Pathway for Biosimilars Act Health Care Reform, Follow-on Biologics, Pharmacy Benefits, Comparative Effectiveness Research, Public Plan Option, Pharmaceutical Pricing, Generic Pharmaceuticals, Healht IT, Medicare Part D, Medicaid, Pharmacy Networks and Contracting

Client expense: $52,597 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Implementation of Consumer Product Safety Improvement Act (CPSIA) of 2008 S.1697 Household Product Labeling Act of 2009 HR.3057 Household Product labeling Act of 2009

Client expense: $1,209,750 · Firm income: Not reported

Government targets: Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)

Legislation to reform private health insurance. Legislation and policies affecting Medicare, Medicaid and healthcare generally, Health I.T.- HR 6357, Healthcare reform, HR 3200 and S. 1697. Oversight of health insurance market generally.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation to reform private health insurance. Legislation and policies affecting Medicare, Medicaid and healthcare generally, Health I.T.- HR 6357, Healthcare reform, HR 3200 and S. 1697. Oversight of health insurance market generally.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Omnibus health Care Reform legislation to be introduced. S. 1213 - A bill to amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Patient-Centered Outcomes Research Trust Fund, and for other purposes. S. 1259 - A bill to protect all patients by prohibiting the use of data obtained from comparative effectiveness research to deny coverage of items or services under Federal health care programs and to ensure that comparative effectiveness research accounts for advancements in personalized medicine and differences in patient treatment response. H. R. 2520 - To provide comprehensive solutions for the health care system of the United States, and for other purposes. H.R. 3200 - To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. S. 1697 - A bill to require that household cleaning products and similar products bear labels that state completely and accurately all of the ingredients of such products, and for other purposes.

Client expense: Not reported · Firm income: $100,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 3200: America's Affordable Health Choices Act of 2009, and various health care reform proposals currently under consideration in Congressional committees. S. 1697:Community Living Assistance Services and Supports Act (CLASS Act)

Client expense: $350,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Labor, Dept of (DOL), SENATE, White House Office

H.R. 3057 & S. 1697, product ingredient communication and consumer product safety issues

Client expense: $70,000 · Firm income: Not reported

Government targets: Consumer Product Safety Commission (CPSC), Council on Environmental Quality (CEQ), Environmental Protection Agency (EPA), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, White House Office